AgomAb Therapeutics NV (AGMB)
Nasdaq: AGMB · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2024
Who runs AgomAb Therapeutics NV
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Knotnerus Tim Jasper
Chief Executive Officer. First filing Mar 2026, latest Oct 7, 2026, 1 filing in all.
Officers reporting now
6
of 13 people with a filing in the last fifteen months
Directors reporting now
7
13 people on the record since 2026
Officerssales are open-market, Nov 6, 2025 to Nov 6, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Knotnerus Tim Jasper | Chief Executive Officer | Mar 2026 | Oct 7, 2026 | none |
| Kemula Pierre Thadee Victor | Chief Financial Officer | Mar 2026 | Oct 7, 2026 | none |
| Borderias Andrea Saez | Chief Development Officer | Mar 2026 | Mar 18, 2026 | none |
| Van Der Horst Paul Henryk | Chief Business Officer | Mar 2026 | Mar 18, 2026 | none |
| Wiesel Philippe Constantin | Chief Medical Officer | Mar 2026 | Mar 18, 2026 | none |
| Lefever Ellen | General Counsel | Mar 2026 | Mar 18, 2026 | none |
Directorssales are open-market, Nov 6, 2025 to Nov 6, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Epstein David R | director | Mar 2026 | Nov 6, 2026 | none |
| Garcia Marino | director | Sep 2026 | Sep 15, 2026 | none |
| Patel Naimish | director | Sep 2026 | Sep 15, 2026 | none |
| Bond Colin Michael | director | Mar 2026 | Mar 18, 2026 | none |
| Hammer Ohad | director | Mar 2026 | Mar 18, 2026 | none |
| Jahreis Angelika Martha | director | Mar 2026 | Mar 18, 2026 | none |
| Verduyn-Van Weegen Felice Isabel | director | Mar 2026 | Mar 18, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.